RAS inhibitors: Potential for cancer therapeutics

Yoel Kloog*, Adrienne D. Cox

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

83 Scopus citations

Abstract

As RAS oncoproteins play a major role in human malignancy, inhibiting RAS function is a promising approach for developing anticancer therapies. Among these approaches are agents such as farnesyltransferase inhibitors (FTIs) and the nontoxic farnesylcysteine analogue farnesylthiosalicylic acid (FTS) that dislodges all RAS isoforms from the membrane, as well as methods to restore regulation of RAS-GTP levels and to alter the interaction of RAS-GTP with downstream targets.

Original languageEnglish
Pages (from-to)398-402
Number of pages5
JournalMolecular Medicine Today
Volume6
Issue number10
DOIs
StatePublished - 2000

Funding

FundersFunder number
United States-Israel Binational Science Foundation

    Fingerprint

    Dive into the research topics of 'RAS inhibitors: Potential for cancer therapeutics'. Together they form a unique fingerprint.

    Cite this